Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with Lamivudine/Zidovudine and efavirenz in study GS-01-934

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 2, 2009, Pages 209-221

  Margot, Nicolas A ^a   Enejosa, Jeff ^a   Cheng, Andrew K ^a   Miller, Michael D ^a   McColl, Damian J ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Drug resistance; Efavirenz; Emtricitabine; Human immunodeficiency virus; Tenofovir DF

Indexed keywords

EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR DISOPROXIL;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUTATION; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS REPLICATION; VIRUS TRANSMISSION;

ADENINE; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DEOXYCYTIDINE; DRUG RESISTANCE, VIRAL; GENOME, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MUTATION, MISSENSE; PHOSPHONIC ACIDS; TREATMENT FAILURE; ZIDOVUDINE;

EID: 70349682997     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b05f7c     Document Type: Article

References (46)

1. Daar ES, Richman DD. Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retroviruses. 2005;21:343-357.
2. Geretti AM. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis. 2007;20:22-32.
3. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-260.
4. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes: a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43:535-540.
5. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008;47:74-78.
6. Schinazi RF, Lloyd RM Jr, Nguyen M-H, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrobial Agents Chemother. 1993;37:875-881.
7. Tisdale M, Kemp SD, Parry NR, et al. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993;90:5653-5656.
8. Margot NA, Waters JM, Miller MD. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrobial Agents Chemother. 2006;50:4087-4095.
9. Borroto-Esoda K, Parkin N, Miller MD. A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine. Antiviral Chemistry and Chemotherapy. 2007;18:297-300.
10. Gu Z, Salomon H, Cherrington JM, et al. K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes crossresistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrobial Agents Chemother. 1995;39:1888-1891.
11. Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy. 1999;4:87-94.
12. Margot NA, Isaacson E, McGowan I, et al. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS. 2002;16:1227-1235.
13. White KL, Margot NA, Wrin T, et al. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184Vand their effects on enzyme function and viral replication capacity. Antimicrobial Agents Chemother. 2002;46: 3437-3446.
14. Margot NA, Isaacson E, McGowan I, et al. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. J Acquir Immune Defic Syndr Hum Retrovirol. 2003;33:15-21.
15. McColl DJ, Margot NA, Wulfsohn M, et al. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. J Acquir Immune Defic Syndr Human Retrovirol. 2004;37:1340-1350.
16. Margot NA, Lu B, Cheng A, et al. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med. 2006; 7:442-450.
17. Ly JK, Margot NA, MacArthur H, et al. The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65R+M184V. Antiviral Chemistry and Chemotherapy. 2007;18:307-316.
18. Delaugerre C, Roudiere L, Peytavin G, et al. Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF. J Clin Virol. 2005;32:241-244.
19. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989;243: 1731-1734.
20. Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A. 1992;89:1934-1938.
21. Harrigan PR, Kinghorn I, Bloor S, et al. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol. 1996;70:5930-5934.
22. Whitcomb JM, Parkin NT, Chappey C, et al. Broad nucleoside reversetranscriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis. 2003;188:992-1000.
23. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004;189: 837-846.
24. Bacheler L, Jeffrey S, Hanna G, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol. 2001;75:4999-5008.
25. Antinori A, Zaccarelli M, Cingolani A, et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Human Retrovirus. 2002;18:835-838.
26. Casado JL, Moreno A, Hertogs K, et al. Extent and importance of crossresistance to efavirenz after nevirapine failure. AIDS Res Human Retrovirus. 2002;18:771-775.
27. Little SJ, Frost SDW, Wong JK, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol. 2008;82:5510-5518.
28. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrobial Agents Chemother. 2000;44:920-928.
29. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2004. Topics in HIV Medicine. 2004;12: 119-124.
30. McColl DJ, Chappey C, Parkin NT, et al. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database. Antiviral Therapy. 2008;13:189-197.
31. Deval J, Navarro J-M, Selmi B, et al. A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. J Biol Chemy. 2004;279: 25489-25496.
32. Frankel FA, Invernizzi CF, Oliveira M, et al. Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations. AIDS. 2007;21:665-675.
33. Borroto-Esoda K, Waters JM, Bae AS, et al. Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. AIDS Res Hum Retroviruses. 2007;23:988-995.
34. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis. 2008;197:867-870.
35. Brenner BG, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS. 2006; 20:F9-F13.
36. Doualla-Bell F, Avalos A, Brenner B, et al. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother. 2006;50:4182-4185. [E-pub October 2006].
37. Mathias AA, Hinkle J, Menning M, et al. Bioequivalence of efavirenz/ emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. J Acquir Immune Defic Syndr. 2007;46:167-173.
38. Piliero PJ. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. JAcquir Immune Defic Syndr. 2004;37(Suppl 1):S2-S12.
39. Back DJ, Burger DM, Flexner CW, et al. The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing. J Acquir Immune Defic Syndr. 2005; 39(Suppl 1):S1-23; quiz S24-S25.
40. Rousseau FS, Wakeford C, Mommeja-Marin H, et al. Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis. 2003;188:1652-1658.
41. Feng JY, Shi J, Schinazi RF, et al. Mechanistic studies show that (-)-FTCTP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. FASEB J. 1999;13:1511-1517.
42. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004; 292:191-201.
43. Molina JM, Gathe J, Lim PL, et al. Comprehensive resistance testing in antiretroviral-naïve patients treated with once-daily lopinavir/ritonavir plus tenofovir DF and emtricitabine: 48-week results from Study 418 [Poster WePeB5701]. Presented at XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand.
44. Elion R, Cohen C, Ward D, et al. BATON Study Group. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naíve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily. HIV Clin Trials. 2008;9:213-224.
45. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of oncedaily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week
46. AIDS. 2008;22:1389-1397.